JPMorgan Reinstates BioCryst Pharma (BCRX) at Overweight

November 20, 2023 3:59 AM EST Send to a Friend
JPMorgan analyst Jessica Fye reinstates coverage on BioCryst Pharma (NASDAQ: BCRX) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login